U.S. Household Products Stock News

NYSE:DOCS
NYSE:DOCSHealthcare Services

Doximity CEO ViVE 2026 Talk Puts AI And Pharma Story In Focus

Doximity (NYSE:DOCS) CEO Jeffrey A. Tangney is scheduled to present at the ViVE 2026 conference. The event will take place in Los Angeles, bringing together leaders across digital health. The appearance underscores Doximity's visibility with health systems, clinicians, and investors. Doximity runs a digital platform for medical professionals, connecting physicians, advanced practice clinicians, and health systems. Conferences like ViVE 2026 can be important forums for companies focused on...
NYSE:NET
NYSE:NETIT

Cloudflare Deepens Security Role With Post Quantum SASE And Mastercard Pact

Cloudflare launched what it calls the first complete Secure Access Service Edge platform with post-quantum encryption across its services. The company also announced a cybersecurity partnership with Mastercard aimed at protecting critical infrastructure and small businesses with real time, risk driven defenses. Cloudflare, trading on the NYSE under ticker NYSE:NET, sits at the intersection of networking and security. This move pushes more of its product stack into the security spotlight...
NYSE:MHK
NYSE:MHKConsumer Durables

Mohawk Industries Weighs Latin America Growth Against Legal And Cost Pressures

Mohawk Industries (NYSE:MHK) has outlined a refreshed expansion and risk profile in its latest 10-K and internal SWOT analysis. The company is pursuing growth in Brazil and Mexico through acquisitions alongside investment in additional manufacturing capacity. Management is putting more emphasis on sustainability and operational efficiency while addressing legal exposures tied to PFAS and silica dust regulations. For investors watching the flooring and surfaces space, Mohawk Industries sits...
NYSE:MUR
NYSE:MUROil and Gas

Murphy Oil Weighs Côte D'Ivoire Dry Wells Against Future Exploration Upside

Murphy Oil, NYSE:MUR, reported two consecutive dry wells in its offshore Côte d'Ivoire exploration campaign. The company is abandoning the Caracal-1X well after non commercial results. Despite these outcomes, Murphy Oil plans to proceed with drilling a third well, Bubale-1X, in a different geological structure. For investors tracking NYSE:MUR, this update comes with the stock at $33.15 and a 1 year return of 31.6%, alongside a 5 year return of 95.6%. At the same time, the stock shows mixed...
NYSE:VST
NYSE:VSTRenewable Energy

Vistra (VST) Margin Compression To 4.2% Tests Bullish Earnings Expansion Narrative

Vistra (VST) has wrapped up FY 2025 with Q4 revenue of US$4.6b, Basic EPS of US$0.55, and net income of US$185m, while trailing twelve month figures show revenue of US$17.7b and Basic EPS of US$2.23 anchored by net income of US$752m. The company has seen quarterly revenue range from US$3.9b to US$5.0b across 2025, with Basic EPS swinging from a Q1 loss of US$0.93 to a Q3 figure of US$1.78. This sets up a results picture where investors are likely to focus on how those earnings translate into...
NYSE:PRMB
NYSE:PRMBBeverage

Primo Brands (PRMB) Q4 Loss Tests Bullish Margin Expansion Narrative

Primo Brands (PRMB) closed FY 2025 with Q4 revenue of US$1.6b and basic EPS of a US$0.07 loss, capping off a trailing twelve month period where revenue reached US$6.7b and EPS came in at US$0.22. Over recent quarters, the company has seen revenue range from US$1.4b in Q4 FY 2024 to US$1.8b in Q3 FY 2025, while quarterly EPS moved between a US$0.49 loss and US$0.24. This set the scene for a year that turned profitable on a trailing basis despite a softer fourth quarter. For investors, the mix...
NasdaqGS:AMBA
NasdaqGS:AMBASemiconductor

Ambarella (AMBA) Quarterly Losses Persist And Reinforce Skeptical Profitability Narratives

Ambarella (AMBA) has just closed out FY 2026 with fourth quarter revenue of US$100.9 million and a basic EPS loss of US$0.38, set against trailing twelve month revenue of US$390.7 million and a TTM EPS loss of US$1.78. Over the past six reported quarters, the company has seen quarterly revenue range from US$82.7 million to US$108.5 million while basic EPS losses have moved between US$0.35 and US$0.58. This gives investors a clear view of how growth ambitions are currently weighing on the...
NYSE:MEG
NYSE:MEGCommercial Services

Is It Too Late To Consider Montrose Environmental Group (MEG) After Its Recent Share Price Surge?

Wondering if Montrose Environmental Group at around US$29.22 is offering fair value today, or if the recent excitement has already been priced in? The stock has logged returns of 26.5% over the last 7 days, 30.2% over the last 30 days, 17.4% year to date and 50.4% over the last year, while the 3 year and 5 year returns sit at 21.4% and 28.6% declines. This price action comes as investors continue to assess Montrose Environmental Group's position in environmental services and its execution on...
NYSE:ESRT
NYSE:ESRTOffice REITs

Is Empire State Realty Trust (ESRT) Pricing Reflect Long-Term Office Demand Concerns?

If you are wondering whether Empire State Realty Trust's current share price reflects its true worth, you are not alone. This article will walk through what the numbers are actually saying about value. The stock last closed at US$5.88, with returns of 0.8% decline over 7 days, 9.8% decline over 30 days, 9.1% decline year to date and 35.4% decline over 1 year. This naturally raises questions about whether the market is reassessing its risks or overlooking potential. Recent coverage around...
NYSE:NRP
NYSE:NRPOil and Gas

Is It Time To Reassess Natural Resource Partners (NRP) After Its Multi Year Rally

If you are looking at Natural Resource Partners and wondering whether the current price reflects its true value, this article will walk you through what the numbers are really saying. The stock closed at US$121.05, with returns of a 1.8% decline over 7 days, 6.0% over 30 days, 16.4% year to date, 19.6% over 1 year and a very large gain over 5 years. This naturally raises questions about how the current price stacks up against fundamentals. Recent interest in Natural Resource Partners has...
NasdaqGS:FIGR
NasdaqGS:FIGRConsumer Finance

Figure Technology Solutions (FIGR) 31% Net Margin Reinforces Bullish Profitability Narrative

Figure Technology Solutions (FIGR) FY 2025 Earnings Snapshot Figure Technology Solutions (FIGR) has capped FY 2025 with Q4 revenue of US$135.6 million and basic EPS of US$0.07, alongside trailing twelve month revenue of US$432.1 million and EPS of US$1.17 that put the latest figures into a fuller context. The company has seen quarterly revenue move from US$67.9 million in Q1 2025 to US$90.0 million in Q2, US$138.5 million in Q3 and US$135.6 million in Q4, while basic EPS has ranged from a...
NYSE:BFLY
NYSE:BFLYMedical Equipment

Assessing Butterfly Network’s Valuation After Record Q4 Growth And First Positive Operating Cash Flow

Butterfly Network (BFLY) is back on investors’ radar after reporting record fourth quarter revenue, 41% year-over-year growth and its first quarter of positive operating cash flow, supported by its Butterfly Embedded platform and Midjourney partnership. See our latest analysis for Butterfly Network. The share price has been volatile around the recent earnings and guidance, with a 27.18% 7 day share price return reversing sharply into an 18.84% 1 day decline. At the same time, the 1 year total...
NasdaqCM:ABTC
NasdaqCM:ABTCSoftware

American Bitcoin (ABTC) Revenue Surge With FY 2025 Loss Tests Bullish Growth Narratives

American Bitcoin (ABTC) has closed out FY 2025 with Q4 revenue of US$78.3 million and a basic EPS loss of US$0.06, alongside trailing twelve month revenue of US$185.2 million and EPS of US$0.17. Over the past few quarters the company has seen revenue move from US$11.6 million in Q3 2024 to US$12.3 million in Q1 2025, US$30.3 million in Q2 2025, US$64.2 million in Q3 2025 and US$78.3 million in Q4 2025, while quarterly EPS has ranged from a loss of US$1.99 in Q1 2025 to a profit of US$0.06 in...
NasdaqGS:MNST
NasdaqGS:MNSTBeverage

Monster Beverage (MNST) Margin Expansion Reinforces Bull Narratives Despite Rich P/E

Monster Beverage (MNST) closed out FY 2025 with fourth quarter revenue of US$2.1 billion and basic EPS of US$0.46, alongside trailing twelve month revenue of US$8.3 billion and EPS of US$1.95 that followed earnings growth of 26.3% over the last year. Over recent periods, the company has seen quarterly revenue move from US$1.9 billion in Q3 2024 to US$2.0 billion in Q4 2024, then to US$1.9 billion in Q1 2025 and US$2.1 billion in both Q2 and Q4 2025, while basic EPS shifted from US$0.38 in Q3...
NasdaqGS:IONS
NasdaqGS:IONSBiotechs

Ionis FDA And Phase 3 Updates Reframe Rare Disease Valuation Story

Ionis Pharmaceuticals (NasdaqGS:IONS) received FDA Priority Review for olezarsen in severe hypertriglyceridemia, indicating an expedited regulatory timeline. New Phase 3 analyses for DAWNZERA, an RNA targeted therapy for hereditary angioedema, are scheduled for presentation at a major scientific forum. These developments focus on two rare disease programs that are central to Ionis’s drug development efforts. Ionis Pharmaceuticals focuses on RNA targeted medicines, with a portfolio that...
NYSE:BRSL
NYSE:BRSLHospitality

Brightstar Lottery Board Shifts Test Capital Returns And Italy Growth Plan

Brightstar Lottery (NYSE:BRSL) has appointed Mariangela Zappia, an international diplomat, as an independent director to its board. The company has announced that CFO Max Chiara will not stand for board re election, with his departure expected after the upcoming shareholder meeting. Brightstar recently secured a nine year renewal of the Italy Lotto licence, supporting a multiyear capital allocation plan and expansion initiatives. Brightstar Lottery, listed on the NYSE under ticker BRSL,...
NYSE:ESTC
NYSE:ESTCSoftware

Elastic ESTC Swings To Q3 Profit Challenging Persistent Loss Making Narrative

Q3 2026 results set up a cleaner earnings story for Elastic (ESTC) Elastic (ESTC) has just posted Q3 2026 revenue of US$449.9 million with basic EPS of US$0.07, alongside trailing twelve month revenue of about US$1.7 billion and a basic EPS loss of US$0.80, giving investors a clearer read on both recent momentum and the still negative full year earnings base. The company has seen quarterly revenue move from US$365.4 million in Q2 2025 to US$449.9 million in Q3 2026, while basic EPS has...
NYSE:BURL
NYSE:BURLSpecialty Retail

Burlington’s 2026 Expansion Plans Test Valuation And Debt Profile

Burlington Stores (NYSE:BURL) plans to open 110 net new stores in 2026, ahead of earlier expectations. The company is also expanding its corporate office footprint in New York to support a larger organization. These moves reflect management's intent to scale operations and reinforce Burlington's long term growth plans. Burlington Stores comes into this announcement with its shares at $306.62 and a 1 year return of 23.0%. Over 3 years the stock has returned 41.8%, and over 5 years 9.8%,...
NYSE:ARLO
NYSE:ARLOElectronic

Arlo Technologies (ARLO) Earnings Turn Positive Challenging Skeptical Profitability Narratives

Arlo Technologies (ARLO) closed out FY 2025 with Q4 revenue of US$141.3 million and basic EPS of US$0.05, alongside net income of US$5.8 million. The trailing 12 month line shows revenue of US$529.3 million and basic EPS of US$0.14 as the business moves further into consistent profitability. Over the past six quarters, the company has seen revenue range from US$119.1 million to US$141.3 million per quarter, with basic EPS shifting from a loss of US$0.05 in late 2024 to positive contributions...
NasdaqGM:ODD
NasdaqGM:ODDPersonal Products

Is Oddity Tech (ODD) Now An Opportunity After A 70% Year To Date Share Price Fall

If you are wondering whether Oddity Tech is now a bargain or a value trap, a closer look at how its current share price lines up with its fundamentals can help frame that question. The stock has seen large price swings recently, with a 7 day return of 63.2% decline, a 30 day return of 64.8% decline, and a year to date return of 70.2% decline, while the 1 year return sits at 75.3% decline from the current last close of US$11.77. These moves have prompted renewed attention on the business, as...
NYSE:CTRI
NYSE:CTRIConstruction

Centuri Holdings Backlog And Expansion Put Record 2025 Profits To Test

Centuri Holdings (NYSE:CTRI) reported record revenue and profitability for 2025. The company secured a 59% increase in backlog to $5.9b, supporting 2026 revenue visibility. Centuri announced expansion into new states and maintained a 100% Master Service Agreement renewal rate. Management is adjusting fleet funding and working to reduce seasonality in its gas business. Centuri Holdings enters 2026 with fresh momentum, backed by record 2025 financial results and a growing project book. The...
NasdaqGS:OS
NasdaqGS:OSSoftware

OneStream (OS) Turns First Quarterly Profit As Bulls Test Profitability Narrative

OneStream (OS) just closed out FY 2025 with Q4 revenue of US$163.7 million, Basic EPS of US$0.01, and net income of US$1.0 million, set against trailing 12 month revenue of US$601.9 million and a loss of US$50.3 million. The company has seen quarterly revenue move from US$132.5 million in Q4 FY 2024 to US$163.7 million in Q4 FY 2025, while Basic EPS shifted from a loss of US$0.10 to a slight profit of US$0.01 over the same period. This frames a story where top line growth is occurring...
NasdaqGS:BBIO
NasdaqGS:BBIOBiotechs

BridgeBio Pharma Sees Pivotal Shift As Late Stage Success Meets Attruby Sales

BridgeBio Pharma (NasdaqGS:BBIO) released positive top line Phase 3 data for Encaleret, BBP-418 and Infigratinib. The company reported strong commercial momentum for its product Attruby, supporting a move toward cash generation. Management framed this combination of clinical and commercial news as a pivotal inflection in the business model. BridgeBio Pharma comes into this update with a current share price of $66.445 and a very large 3 year return, alongside a 90.4% return over the past...
NasdaqGS:FTRE
NasdaqGS:FTRELife Sciences

Fortrea Executive Shuffle Seeks Stronger Clinical Focus And Turnaround Potential

Fortrea Holdings (NasdaqGS:FTRE) has reshaped its executive ranks, naming Scott Dove, PhD, as President of Clinical Pharmacology Services. Oren Cohen, MD, is shifting into a more focused position as Chief Medical Officer, concentrating on Fortrea's medical direction. These changes highlight management's attention on clinical research and development within the broader contract research space. For investors watching Fortrea at a share price of $10.71, the company is pairing leadership moves...